Daiichi Sankyo Japan in den Nachrichten
Globale Innovation und Bereitstellung im Gesundheitswesen
Tamtam hat 20 aktuelle Artikel über Daiichi Sankyo Japan gefunden.
- AstraZeneca/Daiichi Sankyo’s Enhertu® and Datroway® Approved in Japan for First-Line Metastatic Breast Cancer
- Malaysia's IHH's unit loses Tokyo court case against Daiichi Sankyo over Fortis deal
- IHH Healthcare Unit Loses Daiichi Sankyo Court Claim In Japan, Ordered To Bear Litigation Costs
- Daiichi Sankyo bets on new cancer drugs to fuel future growth
- Japan's Daiichi Sankyo unveils five-year business plan focused on oncology innovation
- Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer
- Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
- Japan expert panel OKs Daiichi Sankyo’s MMR vaccine
- Daiichi Sankyo’s Vanflyta secures Korean approval for FLT3-ITD–positive AML
- 第一三共（東証:4568）はENHERTUの中国承認をオンコロジーの優位性に変えるか？
- Is Daiichi Sankyo (TSE:4568) Turning ENHERTU’s China Approval Into a Durable Oncology Advantage?
- Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance
- Is Daiichi Sankyo (TSE:4568) Turning ENHERTU’s China Approval Into a Durable Oncology Moat?
- Japan's Daiichi Sankyo unveils new Toronto headquarters to accelerate investment and innovation in oncology
- Dato-DXd by AstraZeneca and Daiichi Sankyo expected to drive market size of Antibody Drug Conjugates by 2034
- Daiichi Sankyo appoints new head for European research center
- Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
- Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ
- 第一三共(株)【4568】：株価・株式情報
- Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Daiichi Sankyo Japan?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden